Phenomics, lipodystrophy, and the metabolic syndrome

被引:28
作者
Hegele, RA [1 ]
机构
[1] Robarts Res Inst, London, ON N6A 5C1, Canada
关键词
D O I
10.1016/j.tcm.2004.02.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The metabolic syndrome (MetS) is a common multiplex cluster of phenotypes strongly related to cardiovascular disease that includes central obesity with hypertension, dyslipidemia, and type 2 diabetes. The core molecular defect of the MetS is insulin resistance; indeed, the terms "MetS" and "insulin resistance syndrome" often are used interchangeably. The successful translation to clinical medicine of molecular genetic research on other rare monogenic metabolic disorders has stimulated the evaluation of such rare monogenic forms of insulin resistance as partial lipodystrophy resulting from mutations in either LMNA or PPARG genes. Careful phenotypic evaluation of carriers of monogenic insulin resistance using a range of diagnostic methods-an approach sometimes called "phenomics"-may help to find early presymptomatic biomarkers of cardiovascular disease, which, in turn, may uncover new pathways and targets for interventions for the common MetS, diabetes, and atherosclerosis. (C) 2004, Elsevier Inc.
引用
收藏
页码:133 / 137
页数:5
相关论文
共 41 条
  • [1] A novel heterozygous mutation in peroxisome proliferator-activated receptor-γ gene in a patient with familial partial lipodystrophy
    Agarwal, AK
    Garg, A
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (01) : 408 - 411
  • [2] Tyrosine Agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor γ
    Agostini, M
    Gurnell, M
    Savage, DB
    Wood, EM
    Smith, AG
    Rajanayagam, O
    Garnes, KT
    Levinson, SH
    Xu, HE
    Schwabe, JWR
    Willson, TM
    O'Rahilly, S
    Chatterjee, VK
    [J]. ENDOCRINOLOGY, 2004, 145 (04) : 1527 - 1538
  • [3] Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
  • [4] 2-S
  • [5] Barbaro G, 2003, ADV CARDIOL, V40, P97
  • [6] Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension
    Barroso, I
    Gurnell, M
    Crowley, VEF
    Agostini, M
    Schwabe, JW
    Soos, MA
    Maslen, GL
    Williams, TDM
    Lewis, H
    Schafer, AJ
    Chatterjee, VKK
    O'Rahilly, S
    [J]. NATURE, 1999, 402 (6764) : 880 - 883
  • [7] A RECEPTOR-MEDIATED PATHWAY FOR CHOLESTEROL HOMEOSTASIS
    BROWN, MS
    GOLDSTEIN, JL
    [J]. SCIENCE, 1986, 232 (4746) : 34 - 47
  • [8] Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy
    Cao, H
    Hegele, RA
    [J]. HUMAN MOLECULAR GENETICS, 2000, 9 (01) : 109 - 112
  • [9] LMNA is mutated in Hutchinson-Gilford progeria (MIM 176670) but not in Wiedemann-Rautenstrauch progeroid syndrome (MIM 264090)
    Cao, HN
    Hegele, RA
    [J]. JOURNAL OF HUMAN GENETICS, 2003, 48 (05) : 271 - 274
  • [10] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497